Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2013 pp 485–502Cite as

Bronchospasmolytika und Antiasthmatika

  • Chapter

  • 1739 Accesses

Zusammenfassung

Bronchospasmolytika werden zur Behandlung des Asthma bronchiale und der chronisch-obstruktiven Lungenkrankheit (COPD) eingesetzt. Bei beiden Erkrankungen ist es das Ziel, die Bronchialobstruktion, die beim Asthma besser reversibel ist als bei der COPD, zu reduzieren. Im Spätstadium der COPD mit Ateminsuffizienz, Emphysem und Cor pulmonale sollen die Symptome so weit wie möglich gebessert werden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2009): 29. Asthma bronchiale und andere Atemwegserkrankungen: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, Neu-Isenburg: S 771-800.

    Google Scholar 

  • Barnes PJ: (2008). Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8: 183–192.

    Article  PubMed  CAS  Google Scholar 

  • Barnes P. (2012). Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 129: 48–59.

    Article  PubMed  CAS  Google Scholar 

  • Brand PL (2011): Inhaled corticosteroids should be the first line of treatment for children with asthma. Paediatr Respir Rev 12:245–9.

    Article  PubMed  Google Scholar 

  • Buhl R, Berdel D, Criée CP et al. (2006): Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 60: 139–177.

    Article  PubMed  CAS  Google Scholar 

  • Buhl R (2008) Atemwegserkrankungen: Moderne Therapiekonzepte für adäquate Behandlungsstrategien. J Pharmakol Ther 17: 95.

    Google Scholar 

  • Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (1998): Arzneimittel mit problematischer Bioverfügbarkeit. 9. Bekanntmachung gemäß §26, Abs. 3 AMG vom 19.1.1998.

    Google Scholar 

  • Cates CJ, Cates MJ (2008): Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev, July 16: CD006363.

    Google Scholar 

  • Chauhan BF, Chartrand C, Ducharme FM. (2013). Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. Issue 2, Art. No. CD009611.

    Google Scholar 

  • Ducharme FM, Hicks GC (2001): Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. The Cochrane Library, Issue 2. Oxford: Update Software.

    Google Scholar 

  • Ducharme FM, Lasserson TJ, Cates CJ (2006): Lang-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev, Oct 18: CD003137.

    Google Scholar 

  • EMA Press Release (2010): Asthma treatment (long and short-acting Beta agoniststs and anticholinergics): risk of myocardial ischaemia and long-term safety, especially in children. www.ema.europa.eu/docs/en_GB/document_library/Other/2010/07/WC500094267.pdf

  • Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups (2009): Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695–703.

    Google Scholar 

  • FDA Press Release (2010): FDA announces new safety controls for long-acting beta agonists, medications used to treat asthma. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm.

  • FDA Press Release (2011): FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs). www.fda.gov/Drugs/DrugSafety/ucm251512.htm.

  • Gillissen A, Berdel D, Buhl R et al (2007): ß2-Sympathomimetika: Gefahren in der Asthmatherapie? Lehren aus der SMART1-Studie. Dtsch Med Wochenschr 132: 33– 39.

    Article  PubMed  CAS  Google Scholar 

  • GOLD, Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), updated (2013):www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.

  • Haasler I, Buhl R, Taube C (2011): Asthma bronchiale: neue Erkenntnisse und Entwicklungen. Dtsch Med Wochenschr 136: 198–200.

    Article  PubMed  CAS  Google Scholar 

  • Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A (2008): Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 63: 453–462.

    Article  PubMed  CAS  Google Scholar 

  • Kirsch F, Teuner CM, Menn P, Leidl R. (2013). Krankheitskosten für Asthma und COPD bei Erwachsenen in der Bundesrepublik Deutschl and. Gesundheitswesen. Apr 3, Epub ahead of print.

    Google Scholar 

  • Kuehn BM (2009): FDA panel: ban 2 popular asthma drugs. JAMA 301: 365–366.

    Article  PubMed  CAS  Google Scholar 

  • Lemmer B (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82.

    Google Scholar 

  • Lemmer B, Wettengel R (2010): 22. Erkrankungen der Atemwege. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie. 14. Aufl, Springer Verlag, Berlin Heidelberg New York, S. 323-337.

    Google Scholar 

  • Levenson M. (2008). Long-Acting Beta-Agonists and Adverse Asthma Events Meta-Analysis. Statistical Briefing Package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 10-11, 2008. Internet: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf.

  • National-Institutes-of-Health, National-Heart-Lung-and-Blood-Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. NIH Publication No 07-4051 2007, www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (aufgerufen 9.5.2013.

  • Nationale Versorgungsleitlinie Asthma, Version 1.3 (2011). Internet: www.versorgungsleitlinien.de/themen/asthma/pdf/nvl_asthma_lang.pdf, (aufgerufen 9.5.2013).

  • Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group (2006): The salmeterol multicenter asthma research trial: a comparison of unusual pharmacotherapy for asthma or usual pharmacology plus salmeterol. Chest 129: 15–26.

    Google Scholar 

  • Ngkelo A, Adcock IM. (2013). New Treatment for COPD. Current Opinion Pharmacology. 13: 1–8.

    Article  Google Scholar 

  • Patel M, Pilcher JJ, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherhall M, Beasley R, for the SMART Study Group. (2013). Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 1: 32–42.

    Google Scholar 

  • Pedersen S (2006): Clinical safty of inhaled corticosteroids for asthma in children - an update of long-term trials. Drug Safety 29: 599–612.

    Article  PubMed  CAS  Google Scholar 

  • Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, Erwin PJ, West CP. (2013). The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 131: 724–729.

    Article  PubMed  CAS  Google Scholar 

  • Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA (2009): Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Respir Med 103: 1421–1429.

    Article  PubMed  Google Scholar 

  • Schmidt H (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs-Lungenkr 20: 223–231.

    Google Scholar 

  • Singh S, Loke YK, Furberg CD (2008): Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300: 1439–1450.

    Article  PubMed  CAS  Google Scholar 

  • Smolensky M, Lemmer B, Reinberg A (2007): The chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Del Rev 59: 852–882.

    Article  CAS  Google Scholar 

  • Tashkin DP, Celli B, Senn S, Burkhadt D, Kesten S, Menjoge S, Decramer M (2008): A 4-year trial of tiotropium in chronic pulmonary disease. N Engl J Med 359: 1543–1554.

    Article  PubMed  CAS  Google Scholar 

  • Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S (2012):. Efficacy of tiotropium in COPD patients with FEV1 ? 60% participating in the UPLIFT® trial. COPD Mar 20 (Epub ahead of print).

    Google Scholar 

  • The Childhood Asthma Management Program Research Group [CAMP 2000] (2000): Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343: 1054–1063.

    Google Scholar 

  • Vestbo J, Hurd SS, Augusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. (2013). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med. 187: 347–365.

    Article  PubMed  CAS  Google Scholar 

  • Vogelmeier C, Buhl R, Criée CP et al (2007): Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 61: 323–340 (Teil 1); 394–409 (Teil 2).

    Google Scholar 

  • Watts KL, Chavasse RJ. (2012). Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev. May, 16;5:CD006100.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie, Fakultät für Klinische Medizin Mannheim, der Universität Heidelberg, Mannheim, Maybachstraße 14–16, 68169

    Prof. Dr. med. Dr. h.c. Björn Lemmer

Authors
  1. Prof. Dr. med. Dr. h.c. Björn Lemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Lemmer, B. (2013). Bronchospasmolytika und Antiasthmatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation